(PRAX) – Praxis Unveils Perimenopausal Melancholy Trial Information

(PRAX) - Praxis Unveils Perimenopausal Depression Trial Data

  • Praxis Precision Medicines Inc (NASDAQ: PRAX) has reported outcomes from its PRAX-114 Section 2a Half B proof-of-concept trial for perimenopausal melancholy (PMD).
  • PRAX-114 60 mg suspension formulation (n=6) for 14 days in an outpatient setting confirmed fast and sustained enhancements in menopausal and temper signs.
  • Outcomes trended towards baseline following discontinuation of PRAX-114, suggesting the necessity for continued therapy. 
  • PRAX-114 was nicely tolerated, with no change within the general PRAX-114 security profile.
  • Therapy with PRAX-114 resulted in imply decreases from baseline at Day 15 of 60% in frequency of moderate-to-severe sizzling flashes and 68% within the whole rating of the Perimenopausal Melancholy Questionnaire.
  • Therapy with PRAX-114 resulted in imply decreases from baseline at Day 15 of 47% within the HAM-D whole rating, 65% within the HAM-A complete rating, and 40% within the Signs of Melancholy Questionnaire.
  • Praxis Precision plans to advance PRAX-114 to a Section 2b research in ladies with menopausal and temper signs, with trial particulars to be disclosed by the tip of 2021.
  • PRAX-114 is an extrasynaptic GABAA receptor preferring constructive allosteric modulator.
  • Praxis ended Q2 with $339.2 million in money, money equivalents, and marketable securities.
  • Value Motion: PRAX shares are down 6.01% at $12.97 in the course of the market session on the final test Monday.